Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals, Inc. reports developments as a Nasdaq-listed biopharmaceutical company focused on the discovery, development and commercialization of medicines for human disease. Company news commonly covers pipeline updates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders and other cardiometabolic indications, including clinical data presentations for sotagliflozin and pilavapadin.
Recurring updates also include operating and financial results, regulatory interactions, material agreements, financing arrangements and governance or shareholder-voting matters. Coverage of LXRX often connects capital-structure actions with the resources used to advance clinical and preclinical drug candidates.
Lexicon Pharmaceuticals (LXRX) announced a strategic restructuring to eliminate its commercial operations and focus on clinical development following FDA's deficiency letter regarding Zynquista™. The company will reduce its workforce by approximately 60% by December 31st and expects to reduce 2025 operating costs by $100 million, in addition to previously announced $40 million savings.
The company will prioritize its R&D pipeline, including the Phase 2b PROGRESS study of LX9211 for diabetic peripheral neuropathic pain, the Phase 3 SONATA HCM study of sotagliflozin, and IND-enabling studies of LX9851 for obesity. INPEFA® will continue to be available but without promotional efforts.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has appointed Ivan H. Cheung to its Board of Directors. Cheung brings over 25 years of healthcare industry experience and is currently CEO of NextPoint Therapeutics and senior advisor to TPG Growth. He previously served as chairman and CEO of Eisai Inc. from 2016 to July 2023. The appointment coincides with the retirement of Robert J. Lefkowitz, M.D., who departs after 23 years of service on Lexicon's board.
Lexicon Pharmaceuticals (LXRX) announced four studies on sotagliflozin to be presented at the American Heart Association's Sessions 2024 in Chicago. A key secondary analysis of the Phase 3 SCORED trial showed sotagliflozin provided similar relative benefits across all heart failure stages, with increased absolute benefits in earlier stages. The presentations will cover the drug's cardioprotective effects, impact on systolic blood pressure in Type 2 diabetes patients, heart failure staging outcomes, and effects on myocardial contractile work.
Lexicon Pharmaceuticals reported Q3 2024 financial results with net sales of $1.7 million for INPEFA. The company announced an exclusive licensing agreement with Viatris for sotagliflozin outside U.S. and Europe, receiving a $25 million upfront payment with potential for $197 million in additional milestones. Net loss was $64.8 million ($0.18/share). R&D expenses increased to $25.8 million, while SG&A expenses rose to $39.6 million. Cash position stood at $258.4 million. The company completed enrollment screening for Phase 2b PROGRESS study of LX9211, with topline data expected in Q1 2025.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its participation in the Jefferies London Global Healthcare Conference. CEO Mike Exton will join a moderated discussion on Wednesday, November 20, 2024, at 9:00 am GT. The event will be accessible via live webcast in the 'Events' section of Lexicon's website, with the recording remaining available for two weeks after the original broadcast.
Lexicon Pharmaceuticals (LXRX) announced the publication of research findings on sotagliflozin in the Journal of American Society of Nephrology. The study analyzed the drug's efficacy and safety when combined with insulin in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD). Key findings show that sotagliflozin achieved similar HbA1c reductions in both CKD and non-CKD patients, with significant placebo-adjusted reductions of -0.4% for 200mg and -0.3% to -0.4% for 400mg doses. The drug demonstrated a lower to neutral risk of severe hypoglycemia and did not significantly increase diabetic ketoacidosis risk. The FDA has set a PDUFA date of December 20, 2024, for Zynquista (sotagliflozin).
Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its upcoming third quarter 2024 financial results conference call and webcast, scheduled for November 12, 2024, after market close. The management will host a conference call and live webcast at 5:00 p.m. ET to discuss financial results and provide a business update. The event will be accessible via phone and webcast, with replay options available for 7 days via phone and 14 days via webcast on the company's website.
Lexicon Pharmaceuticals (Nasdaq: LXRX) presents data on LX9851, a novel anti-obesity compound, at Obesity Week 2024. Two preclinical studies demonstrate significant findings: First, LX9851 showed substantial reductions in weight, food intake, and fat mass in diet-induced obese mice, particularly when combined with semaglutide. The combination therapy prevented weight regain after semaglutide discontinuation and improved liver-related endpoints.
Second study revealed LX9851's mechanism of action through ACSL5 inhibition, which activates the ileal brake - a natural satiety pathway. The company plans to file an Investigational New Drug (IND) application in 2025 for this first-in-class, orally bioavailable molecule.
Lexicon Pharmaceuticals (LXRX) received an unfavorable vote from the FDA Advisory Committee regarding Zynquista, its oral SGLT1/SGLT2 inhibitor for type 1 diabetes (T1D) and chronic kidney disease (CKD) patients. The committee voted 11-3 against the drug's benefits outweighing its risks. Despite the negative outcome, some committee members expressed support for the drug in certain T1D and CKD sub-populations. The FDA's final decision is expected by December 20, 2024. Currently, only 20% of T1D patients achieve adequate glycemic control with insulin alone, highlighting the potential market need for Zynquista as the first oral medication for T1D patients.
Lexicon Pharmaceuticals announced a new analysis of its Phase 3 SCORED clinical trial demonstrating sotagliflozin's protective effects in patients with diabetic kidney disease (DKD). The post hoc analysis evaluated sotagliflozin's effect on Estimated Glomerular Filtration Rate (eGFR) slope versus placebo. Results showed a placebo-adjusted acute decline in eGFR of -2.59 ml/min/1.73m2/year across 10,574 participants. Notably, sotagliflozin demonstrated greater benefit on chronic slope with increasing baseline albuminuria. The findings will be presented at Kidney Week 2024 in San Diego.